Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo
Name
Enhanced clearance.pdf
Size
803.36 KB
Format
Adobe PDF
Checksum (MD5)
a4d9cd4a7255bfc7795c1c2971798e71
Author(s)
Lu, C.-L.
Bournazos, S.
Schoofs, T.
Halper-Stromberg, A.
Horwitz, J. A.
Nogueira, L.
Golijanin, J.
Gazumyan, A.
Ravetch, J. V.
Caskey, M.
Date Issued
May 2016
Journal
Science
Publisher
American Association for the Advancement of Science (AAAS)
Citation
Lu, C.-L. et al. “Enhanced Clearance of HIV-1-Infected Cells by Broadly Neutralizing Antibodies against HIV-1 in Vivo.” Science 352.6288 (2016): 1001–1004.
Version
Author's final manuscript
Abstract
Anti-retroviral drugs and antibodies limit HIV-1 infection by interfering with the viral life-cycle. In addition, antibodies also have the potential to guide host immune effector cells to kill HIV-1 infected cells. Examination of the kinetics of HIV-1 suppression in infected individuals by passively administered 3BNC117, a broadly neutralizing antibody (bNAb), suggested that the effects of the antibody are not limited to free viral clearance and blocking new infection, but also include acceleration of infected cell clearance. Consistent with these observations, we find that bNAbs can target CD4+ T cells infected with patient viruses and decrease their in vivo half-lives by a mechanism that requires FcγR engagement in a humanized mouse model. The results indicate that passive immunotherapy can accelerate elimination of HIV-1 infected cells.
MIT Department
Institute for Medical Engineering and Science
Massachusetts Institute of Technology. Department of Biological Engineering
Massachusetts Institute of Technology. Department of Chemical Engineering
Massachusetts Institute of Technology. Department of Physics
Ragon Institute of MGH, MIT and Harvard
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1126/science.aaf1279
